Showing 7811-7820 of 9729 results for "".
- Almirall and Inserm Transfert Collaborate to Develop Innovative Treatments for Vitiligohttps://practicaldermatology.com/news/almirall-and-inserm-transfert-collaborate-to-develop-innovative-treatments-for-vitiligo/2461198/Almirall, S.A. and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have entered into a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership, signed by
- Barbie Launches Ken Doll with Vitiligohttps://practicaldermatology.com/news/barbie-launches-ken-doll-with-vitiligo/2461197/Mattel, the parent company for Barbie, will include a Ken doll with vitiligo as part of their 2022 Fashionistas line. The Barbie Fashionistas line includes Barbie dolls with more variety of skin tones, eye colors, hair colors and textures, body types, disabilities, and fashions.
- ISHRS 2022 Practice Consensus Results: Hair Restoration Trendshttps://practicaldermatology.com/news/ishrs-2022-practice-consensus-results-hair-restoration-trends/2461192/The International Society of Hair Restoration Surgery (ISHRS) released resutls of a new member survey that found 68 percent of members performed an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improvement, as ISHRS memb
- Actress Lily Collins is New Living Proof Ambassadorhttps://practicaldermatology.com/news/actress-lily-collins-is-new-living-proof-ambassador/2461174/Actress Lily Collins is the new ambassador for Living Proof. The partnership kicked off with a new brand campaign celebrating its mission of sci
- Cutera to Celebrate AviClear Launch at ASLMShttps://practicaldermatology.com/news/cutera-to-celebrate-aviclear-launch-at-aslms/2461165/Cutera is celebrating the launch of AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, during the ASLMS meeting in San Diego. ASLMS attendees are invited to the celebration for the launch of AviClear on Thursday, April 28,
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat